Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit. METHODS: We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review. RESULTS: Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached. CONCLUSIONS: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).
Cited by 6,181 works. doi:10.1056/nejmoa1501824 Open-access PDF
Authors
- Edward B. Garon
- Naiyer A. Rizvi
- Rina Hui
- Natasha B. Leighl
- Ani Sarkis Balmanoukian
- Joseph P. Eder
- Amita Patnaik
- Charu Aggarwal
- Matthew A. Gubens
- Leora Horn
- Enric Carcereny
- Myung‐Ju Ahn
- Enriqueta Felip
- Jong-Seok Lee
- Matthew David Hellmann
- Omid Hamid
- Jonathan Wade Goldman
- Jean‐Charles Soria
- Marisa P Dolled-Filhart
- Ruth Z. Rutledge
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Hallmarks of Cancer: The Next Generation
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer